Curis (NASDAQ:CRIS) Now Covered by Analysts at StockNews.com

StockNews.com started coverage on shares of Curis (NASDAQ:CRIS) in a research note issued to investors on Thursday. The firm issued a hold rating on the biotechnology company’s stock.

Separately, HC Wainwright reiterated a “buy” rating and issued a $20.00 price objective on shares of Curis in a report on Tuesday, December 10th.

Curis Trading Up 8.0 %

NASDAQ CRIS opened at $2.84 on Thursday. Curis has a 52 week low of $2.57 and a 52 week high of $17.49. The stock has a market cap of $24.05 million, a price-to-earnings ratio of -0.36 and a beta of 3.49. The company has a 50-day moving average price of $3.21 and a two-hundred day moving average price of $4.12.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in the stock. Bleichroeder LP lifted its stake in Curis by 1,982.2% during the fourth quarter. Bleichroeder LP now owns 520,539 shares of the biotechnology company’s stock valued at $1,593,000 after purchasing an additional 495,540 shares during the last quarter. Alyeska Investment Group L.P. acquired a new stake in Curis during the fourth quarter valued at approximately $607,000. Samsara BioCapital LLC acquired a new stake in Curis during the fourth quarter valued at approximately $607,000. CM Management LLC lifted its stake in Curis by 83.3% during the fourth quarter. CM Management LLC now owns 220,000 shares of the biotechnology company’s stock valued at $673,000 after purchasing an additional 100,000 shares during the last quarter. Finally, M28 Capital Management LP lifted its stake in Curis by 23.5% during the fourth quarter. M28 Capital Management LP now owns 521,059 shares of the biotechnology company’s stock valued at $1,594,000 after purchasing an additional 99,108 shares during the last quarter. 29.97% of the stock is currently owned by institutional investors.

Curis Company Profile

Curis, Inc, a biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers in the United States. Its clinical stage drug candidates include Emavusertib, an oral small molecule IRAK4 kinase inhibitor, which is in a Phase 1/2 open-label, single arm expansion trial in patients with relapsed or refractory, or R/R, AML and high-risk myelodysplastic syndromes.